Incidence and management of anaphylactic reactions due to Covid-19 Astrazeneca vaccination at Hanoi Medical University
Main Article Content
Abstract
The purpose of this study is to describe the incidence of anaphylactic reactions after Oxford/AstraZeneca vaccination and management of such reactions. A total of 51,058 people received the first dose of Oxford/AstraZeneca vaccine. Of 48 people (0.0094%) who had anaphylactic reaction of any degree, 58.3% had a history of allergies. The most common symptom was rash (96.8% of reactions). 87.5% of anaphylactic reactions happened within the first 24 hours with 45.2% happened within the first 30 minutes. One case of grade 3 anaphylaxis and two cases of grade 2 anaphylaxis all occurred within 30 minutes of vaccination. Four cases required intramuscular adrenaline injection and one was maintained with adrenaline infusion. All cases with anaphylactic reaction were administered methylprednisolone 40mg and diphenhydramin 10mg. 16.7% of rashes reappeared following the initial treatment. All patients were stable after discharged. AstraZeneca vaccination is safe and anaphylactic reaction management is successful.
Article Details
Keywords
Anaphylaxis, Oxford/AstraZeneca vaccine, COVID-19.
References
2. McNeil M.M., Weintraub E.S., Duffy J et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016; 137: 868-878.
3. Folegatti P.M., Ewer K.J., Aley P.K., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396:467-478.
4. Margitta W., Andrea B., Bettina W.,et al. Practical recommendations for the allergological risk assessment of the COVID-19 vaccination - a harmonized statement of allergy centers in Germany. Allergol Select. 2021; 5: 72-76.
5. Korea Disease Control and Prevention Agency. Updates on COVID-19 in Republic of Korea [press release] [Internet] Cheongju: Korea Disease Control and Prevention Agency; 2021.
6. Shimabukuro T.T., Cole M., Su J.R et al. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA 2021; 325:1101.
7. Gold M.S., MacDonald N.E., McMurtry C.M., et al. Immunization stress-related response - Redefining immunization anxiety-related reaction as an adverse event following immunization. Vaccine 2020; 38:3015.
8. Bộ Y tế. Hướng dẫn tạm thời khám sàng lọc trước tiêm chủng vắc xin phòng COVID-19. Số: /4355 QĐ-BYT.